XBIT 6.92 Stock Price XBiotech Inc.
Range: | 3.54-9.96 | Vol Avg: | 49926 | Last Div: | 0 | Changes: | 0.21 |
Beta: | 1.41 | Cap: | 0.21B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Wed Apr 15 2015 | Empoloyees: | 82 |
CUSIP: | 98400H102 | CIK: | 0001626878 | ISIN: | CA98400H1029 | Country: | US |
CEO: | Mr. John Simard | Website: | https://www.xbiotech.com |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.